Psilocybin for Treatment-Resistant Depression

The Center of Excellence on Mood Disorders is taking part in a worldwide multi-center study investigating the effects of psilocybin in treatment-resistant depression. The study is sponsored by COMPASS Pathways and listed on clinicaltrials.gov.

The study will analyze the effects of a single administration of either 25 mg psilocybin or placebo in patients with treatment-resistant depression. A specially trained study therapist will support every participant before, during and after the psilocybin session. All patients on antidepressants must taper off them within 3-6 weeks prior to baseline (the study team will manage this).

Contact:
Maya Ibrahim
utmooddisorders@uth.tmc.edu 
713-486-2515